Inhibitory effect of double transfection to xenoendothelial cells using both decay accelerating factor and homologous restriction factor 20 genes on complement dependent cytolysis

被引:5
作者
Hayashi, S
Emi, N
Isobe, K
Yokoyama, I
Okada, H
Takagi, H
机构
[1] NAGOYA UNIV,SCH MED,DEPT IMMUNOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN
[2] NAGOYA CITY UNIV,SCH MED,DEPT MOLEC BIOL,MIZUHO KU,NAGOYA,AICHI 467,JAPAN
[3] NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN
关键词
D O I
10.1006/jsre.1996.0099
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hyperacute rejection in discordant xenotransplantation occurs due to the complement activation via classical and/or alternative pathway. Regulator of complement activation (RCA) molecules inhibit species-specific complement dependent cytolysis. To confirm the effect of gene engineering using double RCA molecules on xenogeneic cells, the inhibitory effect on complement dependent cytolysis was compared between bovine aortic endothelial cells (BAEC) doubly transfected with both decay accelerating factor (DAF) and homologous restriction factor (HRF) 20 cDNA and BAEC singly transfected with DAF alone using retroviral vector. The positive percent expression of DAF and HRF20 antigen on double transfectant (BAEC/D + H) was 97.0% and 95.0%, respectively, whereas that of DAF antigen on single transfectant (BAEC/D) was 97.0%. After incubated with 25% human serum and anti-BAEC antibody, the viability of double transfectant (BAEC/D + H) was significantly preserved, compared with that of single transfectant (BAEC/D). These findings demonstrated that xenoendothelial cells doubly transfected with both DAF and HRF20 cDNA could be protected from complement dependent cytolysis more effectively than those singly transfected with DAF alone in the presence of antixenoendothelial antibody. (C) 1996 Academic Press, Inc.
引用
收藏
页码:165 / 169
页数:5
相关论文
共 30 条
[1]  
ABE A, 1993, P SOC EXP BIOL MED, V203, P354
[2]  
AKAMI T, 1992, TRANSPLANT P, V485, P24
[3]  
BACH FH, 1991, HUM IMMUNOL, V262, P30
[4]   RELATIVE ROLES OF DECAY-ACCELERATING FACTOR, MEMBRANE COFACTOR PROTEIN, AND CD59 IN THE PROTECTION OF HUMAN ENDOTHELIAL-CELLS AGAINST COMPLEMENT-MEDIATED LYSIS [J].
BROOIMANS, RA ;
VANWIERINGEN, PAM ;
VANES, LA ;
DAHA, MR .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (12) :3135-3140
[5]  
DALMASSO AP, 1992, AM J PATHOL, V140, P1157
[6]  
HARADA R, 1990, J IMMUNOL, V144, P1823
[7]  
HAYASHI S, 1994, TRANSPLANTATION, V57, P777
[8]  
LI X, 1989, VIROLOGY, V171, P331
[9]  
MANIATIS T, 1982, MOL CLONING, V9
[10]  
MEDOF ME, 1984, J EXP MED, V1558, P160